Subscribe
Jobs
Cars
Real Estate
Apts
Classifieds
Shop
MARIETTA, Pa. – Malaria. Tuberculosis. Alzheimer’s disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler’s diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.
Many could be on the market in five years or less.
Contrast that with five years ago, when so many companies had abandoned the vaccine business that half the U.S. supply of flu shots was lost because of contamination at one of the two manufacturers left.
Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they’re starting to give ailing pharmaceutical makers a shot in the arm.
The lure of big profits, advances in technology and growing government support has been drawing in new companies, from nascent biotechs to Johnson & Johnson, the parent company of Warsaw-based DePuy Orthopaedics Inc. That means recent remarkable strides in overcoming dreaded diseases and annoying afflictions likely will continue.
“Even if a small portion of everything that’s going on now is successful in the next 10 years, you put that together with the last 10 years (and) it’s going to be characterized as a golden era,” says Emilio Emini, Pfizer Inc.’s head of vaccine research.
Vaccines now are viewed as a crucial path to growth as drugmakers look for ways to bolster slowing prescription medicine sales amid intensifying generic competition and government pressure to cut down prices under the federal health overhaul.
Unlike medicines that treat diseases, vaccines help prevent infections by revving up the body’s natural immune defenses against invaders. They are made from viruses, bacteria or parts of them that have been killed or weakened so they generally can’t cause an infection.
Investment in partnerships and other deals to develop and manufacture vaccines has been on a tear – and accelerating since the swine flu pandemic began.
Billions of dollars in government grants are bringing better, faster ways to develop and manufacture vaccines. Rising worldwide emphasis on preventive health care, plus the advent of the first multibillion-dollar vaccines, have further boosted their appeal.
While prescription drug sales are forecast to rise by a third in five years, vaccine sales should double, from $19 billion last year to $39 billion in 2013, according to market research firm Kalorama Information. That’s five times the $8 billion in vaccine sales in 2004.
“What was essentially 25 years ago a rounding error now has become real money,” says Robin Robertson, director of the U.S. Biomedical Advanced Research Development Authority.
That jump is due to a couple of new blockbuster vaccines and rising use of existing ones. The government’s list of recommended vaccines for children has more than doubled since 1985 to 17. It now also calls for a half-dozen vaccines for everyone over 18 and up to four more for some adults.
The past decade brought breakthrough vaccines against pneumococcal disease and rotavirus – two of the world’s top killers – meningitis, cervical cancer and more.
Better technology to create and mass produce vaccines is bringing progress in preventing tropical dengue fever and new threats like superbugs MRSA and C. difficile, even ending addiction to cocaine and nicotine. Success on some vaccines in development, particularly for Alzheimer’s and AIDS, likely would bring billions a year in sales.
Just this fall and early next year, the swine flu vaccines are expected to bring their makers at least a couple billion extra dollars.
That’s despite the five manufacturers for the U.S. not being able to meet an optimistic plan to first make seasonal flu shots and then produce 120 million doses of swine flu vaccine by mid-October – an unprecedented task. But they are steadily catching up with demand.
Unlike most vaccines now “manufactured” in mammal, yeast or other cells – quickly, purely and at high yields – flu vaccines are still grown over many weeks in chicken eggs because it’s economical and those newer, faster methods aren’t U.S.-approved yet. Because swine flu vaccine grew slower than expected, there have been shortages – and lines of anxious consumers.
But a horde of biotech companies, many using multimillion-dollar government grants, already are testing state-of-the-art technology for the next pandemic.
Scientists – including some at J&J’s new vaccine partner, Holland’s Crucell NV – even are working to develop the holy grail: a universal flu vaccine targeting a part of the virus that doesn’t change year to year.
And some future vaccines will come in patches, pills and nasal sprays, rather than painful shots.
In the last century, vaccines dramatically lengthened lifespans by stopping diseases that killed or disabled millions, including smallpox and polio.
After all those successes, many pharmaceutical companies instead focused on lucrative daily pills for chronic diseases.
By the middle of this decade, only a handful were still making vaccines, which are harder to produce than chemical-based pills, making yields unpredictable. That led to the 2004 fiasco when half the U.S. flu shot supply was lost overnight, plus continuing periodic shortages of some kids’ vaccines.
Today, five companies supply flu vaccine: Glaxo- SmithKline; Switzerland’s Novartis AG; Australia’s CSL Biotherapies; MedImmune, part of Britain’s AstraZeneca PLC; and France’s Sanofi-Aventis SA.
There’s been more research on flu vaccines in the past five years than in the previous 20, notes Dr. William Schaffner, Vanderbilt University’s head of preventive medicine and a spokesman for the Infectious Diseases Society of America.
